EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Screening of Germline BRCA1 and BRCA2 Variants in Nigerian Breast Cancer Patients

Abimbola F Onyia iD, Paul Jibrin, Temitope Olatunji-Agunbiade, Ademola Oyekan iD, AbdulRazzaq Lawal, Adewumi Alabi iD, Anthonia C Sowunmi, Eben A Aje, Oluwabusayo B Ogunniyi, Ebenezer S Nkom, Opeyemi C De Campos, Oluwakemi A Rotimi iD und 2 weitere

Technology in Cancer Research & Treatment · 2025

DOI: 10.1177/15330338251333012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Technology in Cancer Research & Treatment, 2025. Verfasst von Abimbola F Onyia und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Covenant University, Ota, Nigeria. Hauptthemen laut MEDLINE: Germ-Line Mutation, BRCA2 Protein, BRCA1 Protein, Genetic Predisposition to Disease. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NHGRI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Breast cancer remains a leading cause of mortality among Nigerian women, with triple-negative breast cancer (TNBC) being particularly prevalent. Variations in BRCA1 and BRCA2 genes remain key risk factors for this disease. However, there are gaps in the frequency and spectrum of these variants in Nigerian populations, as well as a dearth in the local capacity to characterize these variations.

Objective

This study aimed at identifying and characterizing the germline variations in BRCA1/2 in Nigerian breast cancer patients and healthy age-matched controls to understand the genetic risk profile of breast cancer in this population.

Methods

A prospective case-control study was conducted involving 45 breast cancer patients and 51 controls recruited from four major hospitals. DNA was extracted from blood samples, followed by targeted sequencing of BRCA1/2 exonic and intronic regions using the Ampliseq BRCA panel and Illumina MiSeq platform. Variant calling was performed, clinical significance was evaluated on ClinVar and BRCA Exchange databases, and haplotype analysis was performed using NIH LDlink and Haploview 4.2 software.

Results

Pathogenic BRCA1/2 variants were identified in 6.7% of breast cancer patients, all with TNBC and a family history of cancer. Two pathogenic BRCA1 variants were detected: a frameshift deletion BRCA1 c.133_134delAA (p.Lys45 fs) (rs397508857) and a missense variant BRCA1 c.5324T > A (p.Met1775Arg) (rs41293463). A BRCA2 frameshift deletion BRCA2 c.8817_8820del (p.Lys2939 fs) (rs397508010) was also identified. These variants were absent in controls. Haplotype analysis revealed distinct BRCA1 and BRCA2 haplotypes in the breast cancer group.

Conclusion

This study identifies key BRCA1/2 pathogenic variants and unique haplotypes in Nigerian breast cancer patients, highlighting the need for population-specific genetic screening. Integrating genetic testing into breast cancer management strategies could facilitate early detection, personalized treatment planning, and genetic counseling in Nigeria.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Germ-Line MutationBRCA2 ProteinBRCA1 ProteinGenetic Predisposition to DiseaseBreast NeoplasmsHumansFemaleNigeriaMiddle AgedCase-Control StudiesAdultGenetic TestingHaplotypesProspective StudiesAged

Stichwörter der Autor:innen

BRCA1BRCA2Nigeriabreast cancergenetic screeninggermline variantshaplotypes

Substanzen

BRCA2 ProteinBRCA1 ProteinBRCA2 protein, humanBRCA1 protein, human

Autor:innen und Institutionen

  • Department of Biochemistry, Covenant University, Ota, Nigeria.
  • Cancer Genomics Laboratory, Covenant University, Ota, Nigeria.
  • Department of Pathology, National Hospital Abuja, Abuja, Nigeria.
  • Department of Oncology, Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria.
  • NSIA-LUTH Cancer Centre, Lagos University Teaching Hospital, Idi-Araba, Lagos, Nigeria.
  • Department of Surgery, Federal Medical Centre, Abeokuta, Nigeria.

ORCID-Profile: Abimbola F Onyia, Ademola Oyekan, Adewumi Alabi, Oluwakemi A Rotimi

Förderung

  • NCI NIH HHS
  • NHGRI NIH HHS

Zitieren

APA

Onyia, A. F., Jibrin, P., Olatunji-Agunbiade, T., Oyekan, A., Lawal, A., Alabi, A., Sowunmi, A. C., Aje, E. A., Ogunniyi, O. B., Nkom, E. S., De Campos, O. C., Rotimi, O. A., Oyelade, J. O., & Rotimi, S. O. (2025). Screening of Germline BRCA1 and BRCA2 Variants in Nigerian Breast Cancer Patients. Technology in Cancer Research & Treatment. https://doi.org/10.1177/15330338251333012

Vancouver

Onyia AF, Jibrin P, Olatunji-Agunbiade T, Oyekan A, Lawal A, Alabi A, et al. Screening of Germline BRCA1 and BRCA2 Variants in Nigerian Breast Cancer Patients. Technology in Cancer Research & Treatment. 2025. doi:10.1177/15330338251333012

BibTeX
@article{Onyia2025,
  author = {Onyia, Abimbola F and Jibrin, Paul and Olatunji-Agunbiade, Temitope and Oyekan, Ademola and Lawal, AbdulRazzaq and Alabi, Adewumi and Sowunmi, Anthonia C and Aje, Eben A and Ogunniyi, Oluwabusayo B and Nkom, Ebenezer S and De Campos, Opeyemi C and Rotimi, Oluwakemi A and Oyelade, Jelili O and Rotimi, Solomon O},
  title = {Screening of Germline BRCA1 and BRCA2 Variants in Nigerian Breast Cancer Patients},
  journal = {Technology in Cancer Research & Treatment},
  year = {2025},
  doi = {10.1177/15330338251333012}
}
Kostenlos starten →